BACKGROUND AND AIMS: Majority of cases of anal squamous cell carcinoma are human papilloma virus (HPV)-induced and result from anal intraepithelial neoplasia (AIN). This study was conducted to examine methods which may enable the routine diagnosis of HPV-induced changes in the anal rim and the consequences of such detection especially in view of a more sensitive diagnosis of AIN. Results were clinically correlated. METHODS: The study included biopsy samples from 87 patients who had been diagnosed with the following disease patterns: 47 invasive anal carcinoma, 33 AIN of varying severity and seven condylomatous lesions. In 52 of these cases, a tumour was clinically suspected. All biopsies were retrospectively examined for microscopic indications of HPV infection. After microdissection, additional HPV analysis via PCR was carried out. RESULTS: In 38 of 47 cases of anal carcinoma, HPV DNA could be detected via PCR (80.9%), the majority of which were HPV 16 (33/38=86.8%). In 29 of the 33 cases of AIN, HPV DNA was detected (87.9%), most of these in AIN III (15/16=93.8%). Histological markers of HPV infection were detected in all 87 cases. DISCUSSION: In our series, the clinical diagnosis of the invasive anal carcinoma had a high sensitivity of 93.6%, with a specificity of 80%. The positive predictive value was 84.6%, and the negative predictive value 91.4%. In contrast, AIN had been detected clinically in none of the cases. In this situation, especially with high-risk patients, our findings recommend anal HPV screening in combination with anal cytology and anoscopy. CONCLUSION: Based on our results, we urgently recommend for any histological report on excision of anal lesions to include a statement whether histological markers of HPV infection were detected. In individual cases, validation via HPV PCR must be considered.
BACKGROUND AND AIMS: Majority of cases of anal squamous cell carcinoma are human papilloma virus (HPV)-induced and result from anal intraepithelial neoplasia (AIN). This study was conducted to examine methods which may enable the routine diagnosis of HPV-induced changes in the anal rim and the consequences of such detection especially in view of a more sensitive diagnosis of AIN. Results were clinically correlated. METHODS: The study included biopsy samples from 87 patients who had been diagnosed with the following disease patterns: 47 invasive anal carcinoma, 33 AIN of varying severity and seven condylomatous lesions. In 52 of these cases, a tumour was clinically suspected. All biopsies were retrospectively examined for microscopic indications of HPV infection. After microdissection, additional HPV analysis via PCR was carried out. RESULTS: In 38 of 47 cases of anal carcinoma, HPV DNA could be detected via PCR (80.9%), the majority of which were HPV 16 (33/38=86.8%). In 29 of the 33 cases of AIN, HPV DNA was detected (87.9%), most of these in AIN III (15/16=93.8%). Histological markers of HPV infection were detected in all 87 cases. DISCUSSION: In our series, the clinical diagnosis of the invasive anal carcinoma had a high sensitivity of 93.6%, with a specificity of 80%. The positive predictive value was 84.6%, and the negative predictive value 91.4%. In contrast, AIN had been detected clinically in none of the cases. In this situation, especially with high-risk patients, our findings recommend anal HPV screening in combination with anal cytology and anoscopy. CONCLUSION: Based on our results, we urgently recommend for any histological report on excision of anal lesions to include a statement whether histological markers of HPV infection were detected. In individual cases, validation via HPV PCR must be considered.
Authors: Reinhard Bollmann; Gábor Méhes; Robert Torka; Norbert Speich; Christoph Schmitt; Magdolna Bollmann Journal: Cancer Date: 2003-02-25 Impact factor: 6.860
Authors: J M Palefsky; E A Holly; C J Hogeboom; M L Ralston; M M DaCosta; R Botts; J M Berry; N Jay; T M Darragh Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1998-04-01
Authors: J H Scholefield; J Johnson; A Hitchcock; G Kocjan; J H Smith; P A Smith; S Ferryman; P Byass Journal: Cytopathology Date: 1998-02 Impact factor: 2.073
Authors: M Frisch; B Glimelius; A J van den Brule; J Wohlfahrt; C J Meijer; J M Walboomers; H O Adami; M Melbye Journal: Br J Cancer Date: 1998-12 Impact factor: 7.640
Authors: Heun Choi; Hye Won Lee; Hea Won Ann; Jae Kyung Kim; Hua Pyong Kang; Sun Wook Kim; Nam Su Ku; Sang Hoon Han; June Myung Kim; Jun Yong Choi Journal: Infect Chemother Date: 2014-12-29
Authors: Madhur K Garg; Fengmin Zhao; Joseph A Sparano; Joel Palefsky; Richard Whittington; Edith P Mitchell; Mary F Mulcahy; Karin I Armstrong; Nassim H Nabbout; Shalom Kalnicki; Bassel F El-Rayes; Adedayo A Onitilo; Daniel J Moriarty; Thomas J Fitzgerald; Al B Benson Journal: J Clin Oncol Date: 2017-01-09 Impact factor: 44.544
Authors: Stefan Janssen; Jürgen Meier zu Eissen; Gerd Kolbert; Michael Bremer; Johann Hinrich Karstens; Andreas Meyer Journal: Int J Colorectal Dis Date: 2009-08-01 Impact factor: 2.571
Authors: Anna R Giuliano; Guillermo Tortolero-Luna; Elena Ferrer; Ann N Burchell; Silvia de Sanjose; Susanne Kruger Kjaer; Nubia Muñoz; Mark Schiffman; F Xavier Bosch Journal: Vaccine Date: 2008-08-19 Impact factor: 3.641